Terms: = Breast cancer AND NF1, NFNS, 4763, ENSG00000196712, P21359
208 results:
1. Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of breast cancer-Associated Germline Pathogenic Variants in Mexico.
Mesa-Chavez F; Chavarri-Guerra Y; Aguilar-Y-Mendez D; Becerril-Gaitan A; Vaca-Cartagena BF; Carrillo-Bedoya A; Santiesteban-González S; Aranda-Gutierrez A; Rodríguez-Faure A; Obregon-Leal D; Quintero-Beuló G; Rodriguez-Olivares JL; Miaja M; Weitzel JN; Villarreal-Garza C
JCO Glob Oncol; 2024 Apr; 10():e2300417. PubMed ID: 38635940
[TBL] [Abstract] [Full Text] [Related]
2. Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic breast cancer Harboring Altered PI3K/AKT/mTOR.
Wang R; Zhu QY; Ye WW; Huang Y; Chen ZH; Zheng YB; Zou X; Wang J; Jiang DL; Wang XJ; Xu ZY; Cao WM
Discov Med; 2024 Mar; 36(182):527-537. PubMed ID: 38531793
[TBL] [Abstract] [Full Text] [Related]
3. Whole-Genome Sequencing Analysis of Male breast cancer Unveils Novel Structural Events and Potential Therapeutic Targets.
Al Assaad M; Michaud O; Semaan A; Sigouros M; Tranquille M; Phan A; Levine MF; Gundem G; Medina-Martínez JS; Papaemmanuil E; Manohar J; Wilkes D; Sboner A; Hoda SAF; Elemento O; Mosquera JM
Mod Pathol; 2024 Apr; 37(4):100452. PubMed ID: 38369186
[TBL] [Abstract] [Full Text] [Related]
4. breast density in nf1 women: a retrospective study.
De Santis R; Cagnoli G; Rinaldi B; Consonni D; Conti B; Eoli M; Liguori A; Cosentino M; Carrafiello G; Garrone O; Giroda M; Cesaretti C; Sfondrini MS; Gambini D; Natacci F
Fam Cancer; 2024 Mar; 23(1):35-40. PubMed ID: 38270845
[TBL] [Abstract] [Full Text] [Related]
5. Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers.
Cobleigh MA; Layng KV; Mauer E; Mahon B; Hockenberry AJ; Abukhdeir AM
Breast Cancer Res Treat; 2024 Apr; 204(2):407-414. PubMed ID: 38153569
[TBL] [Abstract] [Full Text] [Related]
6. First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative breast cancer: Clinical and Biomarker Results.
Schmid P; Turner NC; Barrios CH; Isakoff SJ; Kim SB; Sablin MP; Saji S; Savas P; Vidal GA; Oliveira M; O'Shaughnessy J; Italiano A; Espinosa E; Boni V; White S; Rojas B; Freitas-Junior R; Chae Y; Bondarenko I; Lee J; Torres Mattos C; Martinez Rodriguez JL; Lam LH; Jones S; Reilly SJ; Huang X; Shah K; Dent R
Clin Cancer Res; 2024 Feb; 30(4):767-778. PubMed ID: 38060199
[TBL] [Abstract] [Full Text] [Related]
7. Omics sciences and precision medicine in sarcoma.
Bonetti G; Donato K; Dhuli K; Gadler M; Benedetti S; Guerri G; Cristofoli F; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Bernini A; Fulcheri E; Cavalca D; Stuppia L; Stuppia L; Gatta V; Cristoni S; Cecchin S; Marceddu G; Bertelli M
Clin Ter; 2023; 174(Suppl 2(6)):68-76. PubMed ID: 37994750
[TBL] [Abstract] [Full Text] [Related]
8. Genetic Aspects of Conjunctival Melanoma: A Review.
Chang E; Demirci H; Demirci FY
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761808
[TBL] [Abstract] [Full Text] [Related]
9. IGF2BP3 mediates the mRNA degradation of nf1 to promote triple-negative breast cancer progression via an m6A-dependent manner.
Zhang X; Shi L; Sun HD; Wang ZW; Xu F; Wei JF; Ding Q
Clin Transl Med; 2023 Sep; 13(9):e1427. PubMed ID: 37743642
[TBL] [Abstract] [Full Text] [Related]
10. Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary breast and Ovarian cancer.
Desai NV; Barrows ED; Nielsen SM; Hatchell KE; Anderson MJ; Haverfield EV; Herrera B; Esplin ED; Lucassen A; Tung NM; Isaacs C
JCO Precis Oncol; 2023 Aug; 7():e2200695. PubMed ID: 37535880
[TBL] [Abstract] [Full Text] [Related]
11. Proteogenomic Approaches for the Identification of nf1/Neurofibromin-depleted Estrogen Receptor-positive breast cancers for Targeted Treatment.
Kim BJ; Zheng ZY; Lei JT; Holt MV; Chen A; Peng J; Fandino D; Singh P; Kennedy H; Dou Y; Chica-Parrado MDR; Bikorimana E; Ye D; Wang Y; Hanker AB; Mohamed N; Hilsenbeck SG; Lim B; Asirvatham JR; Sreekumar A; Zhang B; Miles G; Anurag M; Ellis MJ; Chang EC
Cancer Res Commun; 2023 Jul; 3(7):1366-1377. PubMed ID: 37501682
[TBL] [Abstract] [Full Text] [Related]
12. Longitudinal adherence to breast cancer surveillance following cancer genetic testing in an integrated health care system.
Knerr S; Guo B; Wernli KJ; Mittendorf KF; Feigelson HS; Gilmore MJ; Jarvik GP; Kauffman TL; Keast E; Liles EG; Lynch FL; Muessig KR; Okuyama S; Veenstra DL; Zepp JM; Wilfond BS; Devine B; Goddard KAB
Breast Cancer Res Treat; 2023 Oct; 201(3):461-470. PubMed ID: 37470892
[TBL] [Abstract] [Full Text] [Related]
13. PDE4DIP contributes to colorectal cancer growth and chemoresistance through modulation of the nf1/RAS signaling axis.
Pan R; Dai J; Liang W; Wang H; Ye L; Ye S; Lin Z; Huang S; Xiong Y; Zhang L; Lu L; Wang O; Shen X; Liao W; Lu X
Cell Death Dis; 2023 Jun; 14(6):373. PubMed ID: 37355626
[TBL] [Abstract] [Full Text] [Related]
14. A comprehensive study on surveillance outcomes of a male population followed at a hereditary breast cancer high-risk consultation at a Portuguese tertiary hospital.
Oliveira MJ; Costa S; Magalhães A; Garrido L; Peleteiro B; Fougo JL; Castedo S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11145-11156. PubMed ID: 37347260
[TBL] [Abstract] [Full Text] [Related]
15. Clinical and imaging modality factors impacting radiological interpretation of breast screening in young women with neurofibromatosis type 1.
Wilding M; Fleming J; Moore K; Crook A; Reddy R; Choi S; Schlub TE; Field M; Thiyagarajan L; Thompson J; Berman Y
Fam Cancer; 2023 Oct; 22(4):499-511. PubMed ID: 37335380
[TBL] [Abstract] [Full Text] [Related]
16. Giant juvenile fibroadenomas with and without prominent pseudoangiomatous stromal hyperplasia (PASH)-like change: clinicopathological and molecular characteristics.
Jorns JM; Farooq A; Puzyrenko A; Jarzembowski J; Thike AA; Nasir NDM; Ng CCY; Liu W; Lee JY; Lim AH; Guan P; Teh BT; Tan PH
Histopathology; 2023 Sep; 83(3):357-365. PubMed ID: 37140543
[TBL] [Abstract] [Full Text] [Related]
17. Exploiting metabolic vulnerabilities in breast cancers with nf1 loss.
Yap YS; Hu J
Cell Rep Med; 2023 Apr; 4(4):101010. PubMed ID: 37075699
[TBL] [Abstract] [Full Text] [Related]
18. N-acetylcysteine overcomes nf1 loss-driven resistance to PI3Kα inhibition in breast cancer.
Auf der Maur P; Trefny MP; Baumann Z; Vulin M; Correia AL; Diepenbruck M; Kramer N; Volkmann K; Preca BT; Ramos P; Leroy C; Eichlisberger T; Buczak K; Zilli F; Okamoto R; Rad R; Jensen MR; Fritsch C; Zippelius A; Stadler MB; Bentires-Alj M
Cell Rep Med; 2023 Apr; 4(4):101002. PubMed ID: 37044095
[TBL] [Abstract] [Full Text] [Related]
19. Long-term Survival in breast cancer Patients Is Associated with Contralateral Parenchymal Enhancement at MRI: Outcomes of the SELECT Study.
Ragusi MAA; van der Velden BHM; Meeuwis C; Tetteroo E; Coerkamp EG; van Nijnatten TJA; Jansen FH; Wolters-van der Ben EJM; Jongen L; van Raamt F; Dorrius MD; Verloop J; Viergever MA; Pijnappel RM; Elias SG; Gilhuijs KGA
Radiology; 2023 May; 307(4):e221922. PubMed ID: 36975820
[TBL] [Abstract] [Full Text] [Related]
20. ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.
Chen JW; Jacot W; Cortés J; Krop IE; Dent S; Harbeck N; De Laurentiis M; Diéras V; Im YH; Stout TJ; Schimmoller F; Savage HM; Hutchinson KE; Wilson TR
Mol Oncol; 2023 Oct; 17(10):2000-2016. PubMed ID: 36892268
[TBL] [Abstract] [Full Text] [Related]
[Next]
